VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

AAN 2021 | STOP 301: non-oral INP104 for the acute treatment of migraine

Jessica Ailani, MD, FAAN, Medstar Georgetown University Hospital, Washington, DC, outlines the details of the ‘Acute therapies for migraine’ industry therapeutic update session at AAN 2021. The session focuses on dihydroergotamine use, and the benefits of non-oral medications for patients with migraine. Data from the Phase III STOP 301 study (NCT03557333) of INP104 for the acute treatment of migraine will be presented. INP104, dihydroergotamine mesylate, uses a novel ‘precision olfactory delivery’ (POD) system to target the vascular-rich upper nasal cavity. This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting.

Disclosures

Consulting: (Honoraria for independent consulting) Amgen, Abbvie, Biohaven, Eli Lilly and Company, Lundbeck, Teva, Impel, Satsuma, Theranica, Axsome, Neso, GlaxoSmithKline, Aeon, Medscape
Ownership of Stocks: CtrM
Speakers Bureau: (Honoraria for promotional speaking) Allergan/Abbvie, Amgen, Biohaven, Eli Lilly and Company, Lundbeck, Teva
Editorial services: (Honoraria) Current Pain and Headache Reports, Section editor, Unusual Headache Syndromes, NeurologyLive, SELF (medical reviewer)
Clinical Trial Grants: (Fees to Institution) American Migraine Foundation, Allergan, Biohaven, Eli Lilly and Company, Satsuma, Zosano